Arthneeti
All Q2 FY26 results →
OP

Orchid Pharma Ltd

Q2 FY26Pharmaceuticals & Biotechnology

Orchid Pharma Q2 FY26 earnings call: Revenue & Margins

Q2 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹1,002
Market cap₹9.4K Cr
P/E348.0
Updated23 Aug 2026
Read4 min read

The short version

Financial year 2026 expected to remain muted operationally with no signs of market recovery in the current year. FY26 is expected to be muted operationally as the company focuses on building a stronger foundation for recovery and sustainable growth (Page 14).

From Orchid Pharma Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Financial year 2026 expected to remain muted operationally with no signs of market recovery in the current year.
  • Focus on building a stronger foundation for recovery and sustainable long-term growth.
  • Global antibiotics market continues to face prolonged slowdown; no immediate revival signs.
  • New licensing deals anticipated for Exblifep in multiple geographies to drive future revenues.
  • Expansion of AMS division to build hospital sales volume, aiming for breakeven by Q4 FY26.
  • Enmetazobactam and Cefiderocol projects progressing; Cefiderocol production expected by Q4 FY26.
  • Growth driven through partnerships and licensing in regulated and unregulated markets globally, including India, Europe, U.S., Latin America, and Southeast Asia.

2 more points from Orchid Pharma Ltd's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

See what Orchid Pharma Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • The 7ACA project is progressing as per revised timelines with all fermenters erected and major equipment installation ongoing. This project aims to strengthen Orchid's API manufacturing base and reduce import dependency.
  • The Cefiderocol project building structure is nearly complete, with equipment deliveries started, targeting production readiness by Q4 of FY26.
  • Operational discipline focuses on maintaining cost stability amid inflation and market pressures.
  • The company is investing in expanding its AMS (Antimicrobial Stewardship) division as a strategic platform, especially for launching Cefiderocol in India.

2 more points from Orchid Pharma Ltd's call on capex

Pro opens every point from 15K+ earnings calls

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Orchid Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript from the Orchid Pharma Limited Q2 FY26 earnings call does not explicitly mention the current or expected order book or pending orders. Key related points are: - The company is focused on signing new licensing deals, especially for Exblifep (Enmetazobactam) in multiple geographies, but concrete progress on new licensing is expected over the coming quarters. - The sales of Orblicef (domestic brand) are progressing well and hospital sales through the AMS division are expanding. - There are ongoing negotiations for partners in the U.S. and other global markets for out-licensing Enmetazobactam.

2 more points from Orchid Pharma Ltd's call on order book

Pro opens every point from 15K+ earnings calls

Orchid Pharma Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27

Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹304 Cr, net profit ₹3 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Orchid Pharma Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Bajaj Healthcare (Q2 FY26)

    For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

  • Infinium Pharma (Q2 FY26)

    Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium

  • Wanbury (Q2 FY26)

    Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q2 FY26)

    Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Orchid Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Orchid Pharma Ltd Q2 FY26 results?

Financial year 2026 expected to remain muted operationally with no signs of market recovery in the current year. FY26 is expected to be muted operationally as the company focuses on building a stronger foundation for recovery and sustainable growth (Page 14).

What is Orchid Pharma Ltd share price analysis?

Orchid Pharma Ltd currently shows a neutral. The stock trades at a P/E of 348.0 with a market cap of ₹9,439 Cr. Investors should review the full earnings analysis for detailed insights.

Is Orchid Pharma Ltd planning capital expenditure?

The 7ACA project is progressing as per revised timelines with all fermenters erected and major equipment installation ongoing.

Keep Orchid Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.